Generation Bio Q1 net loss $74.5M on lease termination; cash runway into 2H 2027

Generation Bio Co.

2024-Q1 EPS reported -$1.12 revenue$4,059,000

Q1 net loss $74.5M ($1.12/share) includes $56.9M non-cash lease termination charge; vs $32.1M ($0.53) Q1 2023.
Cash $233.9M at March 31, 2024; expected to fund operations into 2H 2027.
Presented in vivo T cell delivery data for ctLNP at ASGCT; advancing HSC-targeted ctLNP for sickle cell/beta-thalassemia.
R&D expenses $14.3M, down from $22.0M YoY; G&A $10.4M, down from $12.9M.
Collaboration with Moderna for T cell ctLNP; iqDNA platform using rapid enzymatic synthesis advanced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Generation Bio Co. reported the quarter ended March 31, 2024 results: net income Net loss was $74.5 million, or $1.12 basic and diluted net loss per share.

Period: the quarter ended March 31, 2024
Net income: Net loss was $74.5 million, or $1.12 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-007959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.